The Medicare GLP-1 Bridge (launching July 1, 2026, through December 31, 2027) provides weight-loss access to Wegovy at a fixed $50 per month copay outside Part D this $50 does not count toward the deductible, TrOOP, or the $2,100 OOP cap
Zepbound vs Mounjaro for Weight Loss Results A clinical trial for Zepbound and Mounjaro that involved two randomised, placebo-controlled, 72-week-long studies in over 3,400 adults with obesity revealed interesting findings
Subgroup analyses (duration of trial, type of medication) and sensitivity analyses (secondary prevention, T2DM only) were conducted
10.1046/j.1365-2559.1999.00786.x 29
www.pendulumlife.com New Products New Products Related Articles Vibrant Health Launches 3-in-1 Multi/Probiotic/Omega-3 Supplement Vitamin Shoppe Line of Supplements Formulated to Support GLP-1 Users Circana Weighs Impact of GLP-1 on Consumer Spending Rebecca Viscomi is the Multimedia Editor at WholeFoods Magazine